In simulating a personalized treatment strategy for the subgroups ROS1, BRAFv600E, and NTRK(1, 2, 3), it was assumed that crizotinib in ROS1 has similar effectiveness as crizotinib in the ALK subgroup35, dabrafenib and trametinib were equally effective in NSCLC BRAFv600E as in melanoma BRAFval60069, and larotrectinib in NTRK(1, 2, 3), it was assumed to have a PFS HR similar to that of the prognostic value of EGFRclassic40. This evidence concerns the gene ALK and melanoma.